Recently, Capstan reported that their in vivo anti-CD19 CAR-T cell therapy enabled by CD5- or CD8-tLNPs could clear Nalm6 tumor with high efficiency and specificity in a humanized mouse model, highlighting the potential for clinical development.123. Here, CD8A is linked to neoplasm.